Efficacy and safety of CD5024 1% in acne vulgaris

Trial Profile

Efficacy and safety of CD5024 1% in acne vulgaris

Phase of Trial: Phase II

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs Ivermectin (Primary) ; Adapalene/benzoyl peroxide
  • Indications Acne vulgaris
  • Focus Therapeutic Use
  • Sponsors Galderma
  • Most Recent Events

    • 21 Dec 2016 Status changed from recruiting to completed.
    • 22 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top